Cadrenal Therapeutics, Inc.: Executive or director change
Cadrenal Therapeutics stockholders approved all proposals at the 2026 annual meeting, including an equity plan expansion and warrant share issuance.
Neutral newsWhat happened
- Stockholders re-elected Quang X. Pham as a Class I director to serve until the 2029 annual meeting.
The full interpretation is in the app
Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.
Read the full interpretation